ARK E021

Drug Profile

ARK E021

Alternative Names: ARK-E021

Latest Information Update: 22 Sep 2015

Price : $50

At a glance

  • Originator M Arkin 1999 Ltd
  • Developer Foamix; M Arkin 1999 Ltd
  • Class Antiacnes
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne vulgaris

Most Recent Events

  • 31 Oct 2013 M Arkin 1999 Ltd and Foamix complete a phase I/II trial in Acne vulgaris in Israel (NCT01494285)
  • 30 Jun 2012 Phase-I/II clinical trials in Acne vulgaris in Israel (Topical)
  • 15 Dec 2011 Preclinical trials in Acne vulgaris in Israel (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top